Bu-Cy-Etoposide Conditioning for Lymphomas Undergoing Autologous Stem Cell Transplantation: Long Term Outcomes

Thomas Atkinson, MD; Zaid Al-Quarayshi, MD; Yordanka Koleva, MPH; Reinhold Munker, MD; Nakhle Saba, MD; Alan Miller, MD, PhD; Roy Weiner, MD; Hana Safah, MD
 

Autologous hematopoietic stem cell transplantation is widely used for relapsed Hodgkin and non-Hodgkin lymphomas and can result in long-term remissions or even cures. The optimal conditioning regimen for autologous transplantation remains to be determined. The objective of this study is to describe long-term outcomes of the B-C-E (busulfan- cyclophosphamide and etoposide) protocol at our center. A retrospective analysis of all patients undergoing autologous transplant using the BCE regimen was performed. A total of 51 patients (24 Hodgkin and 27 non-Hodgkin lymphomas) were treated between 1998 and 2015. At five years, the overall survival was 44.2% and the freedom from progression 21.2%. No statistical differences in outcomes were found between disease types or according to age at transplant, gender or ethnicity. The long-term outcome was best for patients who reached complete remission after transplant. In conclusion, BCE has manageable toxicity, compares well with other preparative regimens and can result in long-term survival. Remission after autologous transplantation is a platform for innovative approaches to increase cure rates.    

Login to read full article

 

Member Login